Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
A systems biology approach identifies the role of dysregulated PRDM6 in the development of hypertension
Kushan L. Gunawardhana, … , James P. Noonan, Arya Mani
Kushan L. Gunawardhana, … , James P. Noonan, Arya Mani
Published January 5, 2023
Citation Information: J Clin Invest. 2023;133(4):e160036. https://doi.org/10.1172/JCI160036.
View: Text | PDF
Research Article Cardiology Nephrology

A systems biology approach identifies the role of dysregulated PRDM6 in the development of hypertension

  • Text
  • PDF
Abstract

Genetic variants in the third intron of the PRDM6 gene have been associated with BP traits in multiple GWAS. By combining fine mapping, massively parallel reporter assays, and gene editing, we identified super enhancers that drive the expression of PRDM6 and are partly regulated by STAT1 as the causal variants for hypertension. The heterozygous disruption of Prdm6 in mice expressing Cre recombinase under the control of mouse smooth muscle cell protein 22-α promoter (Prdm6fl/+ SM22-Cre) exhibited a markedly higher number of renin-producing cells in the kidneys at E18.5 compared with WT littermates and developed salt-induced systemic hypertension that was completely responsive to the renin inhibitor aliskiren. Strikingly, RNA-Seq analysis of the mouse aortas identified a network of PRDM6-regulated genes that are located in GWAS-associated loci for blood pressure, most notably Sox6, which modulates renin expression in the kidney. Accordingly, the smooth muscle cell–specific disruption of Sox6 in Prdm6fl/+ SM22-Cre mice resulted in a dramatic reduction of renin. Fate mapping and histological studies also showed increased numbers of neural crest–derived cells accompanied by increased collagen deposition in the kidneys of Prdm6fl/+ Wnt1Cre-ZsGreen1Cre mice compared with WT mice. These findings establish the role of PRDM6 as a regulator of renin-producing cell differentiation into smooth muscle cells and as an attractive target for the development of antihypertensive drugs.

Authors

Kushan L. Gunawardhana, Lingjuan Hong, Trojan Rugira, Severin Uebbing, Joanna Kucharczak, Sameet Mehta, Dineth R. Karunamuni, Brenda Cabera-Mendoza, Neeru Gandotra, Curt Scharfe, Renato Polimanti, James P. Noonan, Arya Mani

×

Figure 1

GWAS lead SNPs in PRDM6 intron 3 and their CRISPR deletion.

Options: View larger image (or click on image) Download as PowerPoint
GWAS lead SNPs in PRDM6 intron 3 and their CRISPR deletion.
(A) Genetic ...
(A) Genetic variants in PRDM6 gene discovered by GWAS of BP traits. (B) LD structure of rs13359291, rs2287696, rs1422279, and rs555625 in the East Asian population. R2 and D’ for each SNP pair is represented inside corresponding boxes. (C) Relationship between lead SNPs, open chromatin regions, and histone marks. (50, 51, 52, 53, 54). (D) Schematic of CRISPR-Cas9–mediated deletion of the approximately 22 kb LD region in intron 3, encompassing all lead SNPs, HEK293T, n = 4 technical replicates (E) Expression of PRDM6 in different human cell lines (www.proteinatlas.org/). (F) Significant reduction of PRDM6 mRNA expression upon deletion of the LD region compared with the WT sequence assayed by RT-qPCR, identifying the intronic region as an enhancer locus for PRDM6. n = 4. Unpaired, 2 tailed, t test, n = 4 technical replicates. ****P < 0.0001. NES, normalized effect size.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts